Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer's Disease and Brain Ischemia

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Oct 29

PMID 33114455

Citations 13

Authors

Veronika Prikhodko

Daria Chernyuk

Yurii Sysoev

Nikita Zernov

Sergey Okovityi

Elena Popugaeva

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease and cerebral ischemia are among the many causative neurodegenerative diseases that lead to disabilities in the middle-aged and elderly population. There are no effective disease-preventing therapies for these pathologies. Recent in vitro and in vivo studies have revealed the TRPC6 channel to be a promising molecular target for the development of neuroprotective agents. TRPC6 channel is a non-selective cation plasma membrane channel that is permeable to Ca. Its Ca-dependent pharmacological effect is associated with the stabilization and protection of excitatory synapses. Downregulation as well as upregulation of TRPC6 channel functions have been observed in Alzheimer's disease and brain ischemia models. Thus, in order to protect neurons from Alzheimer's disease and cerebral ischemia, proper TRPC6 channels modulators have to be used. TRPC6 channels modulators are an emerging research field. New chemical structures modulating the activity of TRPC6 channels are being currently discovered. The recent publication of the cryo-EM structure of TRPC6 channels should speed up the discovery process even more. This review summarizes the currently available information about potential drug candidates that may be used as basic structures to develop selective, highly potent TRPC6 channel modulators to treat neurodegenerative disorders, such as Alzheimer's disease and cerebral ischemia.

Citing Articles

Calcium Ions in the Physiology and Pathology of the Central Nervous System.

Pikor D, Hurla M, Slowikowski B, Szymanowicz O, Poszwa J, Banaszek N Int J Mol Sci. 2024; 25(23).

PMID: 39684844 PMC: 11642227. DOI: 10.3390/ijms252313133.

Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.

Ali N, Al-Kuraishy H, Al-Gareeb A, Hadi N, Assiri A, Alrouji M Cell Mol Neurobiol. 2024; 44(1):55.

PMID: 38977507 PMC: 11230952. DOI: 10.1007/s10571-024-01489-y.

Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer's Disease.

Baracaldo-Santamaria D, Avendano-Lopez S, Ariza-Salamanca D, Rodriguez-Giraldo M, Calderon-Ospina C, Gonzalez-Reyes R Int J Mol Sci. 2023; 24(10).

PMID: 37240413 PMC: 10218981. DOI: 10.3390/ijms24109067.

Elderly with Varying Extents of Cardiac Disease Show Interindividual Fluctuating Myocardial TRPC6-Immunoreactivity.

Federspiel J, Gartner J, Lipp P, Schmidt P, Tschernig T J Cardiovasc Dev Dis. 2023; 10(1).

PMID: 36661921 PMC: 9861266. DOI: 10.3390/jcdd10010026.

New Positive TRPC6 Modulator Penetrates Blood-Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice.

Zernov N, Veselovsky A, Poroikov V, Melentieva D, Bolshakova A, Popugaeva E Int J Mol Sci. 2022; 23(21).

PMID: 36362339 PMC: 9653995. DOI: 10.3390/ijms232113552.

References

Zhang Y, Yu P, Liu H, Yao H, Yao S, Yuan S . Hyperforin improves post-stroke social isolation‑induced exaggeration of PSD and PSA via TGF-β. Int J Mol Med. 2018; 43(1):413-425. PMC: 6257831. DOI: 10.3892/ijmm.2018.3971. View

Bojarski L, Pomorski P, Szybinska A, Drab M, Skibinska-Kijek A, Gruszczynska-Biegala J . Presenilin-dependent expression of STIM proteins and dysregulation of capacitative Ca2+ entry in familial Alzheimer's disease. Biochim Biophys Acta. 2008; 1793(6):1050-7. DOI: 10.1016/j.bbamcr.2008.11.008. View

Yao C, Zhang J, Liu G, Chen F, Lin Y . Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. Mol Med Rep. 2013; 9(1):69-76. DOI: 10.3892/mmr.2013.1778. View

Dirnagl U, Iadecola C, Moskowitz M . Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22(9):391-7. DOI: 10.1016/s0166-2236(99)01401-0. View

Butterfield D, Reed T, Sultana R . Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic Res. 2010; 45(1):59-72. DOI: 10.3109/10715762.2010.520014. View

Pochwat B, Szewczyk B, Kotarska K, Rafalo-Ulinska A, Siwiec M, Sowa J . Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice. Front Mol Neurosci. 2019; 11:456. PMC: 6299069. DOI: 10.3389/fnmol.2018.00456. View

Guinamard R, Simard C, Del Negro C . Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013; 138(2):272-84. PMC: 4116821. DOI: 10.1016/j.pharmthera.2013.01.012. View

Muller M, Essin K, Hill K, Beschmann H, Rubant S, Schempp C . Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J Biol Chem. 2008; 283(49):33942-54. PMC: 2662218. DOI: 10.1074/jbc.M801844200. View

Shen H, Pan J, Pan L, Zhang N . TRPC6 inhibited NMDA current in cultured hippocampal neurons. Neuromolecular Med. 2013; 15(2):389-95. DOI: 10.1007/s12017-013-8226-1. View

10.

Ryazantseva M, Goncharova A, Skobeleva K, Erokhin M, Methner A, Georgiev P . Presenilin-1 Delta E9 Mutant Induces STIM1-Driven Store-Operated Calcium Channel Hyperactivation in Hippocampal Neurons. Mol Neurobiol. 2017; 55(6):4667-4680. DOI: 10.1007/s12035-017-0674-4. View

11.

Chaudhuri P, Colles S, Damron D, Graham L . Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain. Arterioscler Thromb Vasc Biol. 2003; 23(2):218-23. DOI: 10.1161/01.atv.0000052673.77316.01. View

12.

Urban N, Wang L, Kwiek S, Rademann J, Kuebler W, Schaefer M . Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. Mol Pharmacol. 2015; 89(1):197-213. DOI: 10.1124/mol.115.100792. View

13.

Wang R, Reddy P . Role of Glutamate and NMDA Receptors in Alzheimer's Disease. J Alzheimers Dis. 2016; 57(4):1041-1048. PMC: 5791143. DOI: 10.3233/JAD-160763. View

14.

Sun Y, Sukumaran P, Bandyopadhyay B, Singh B . Physiological Function and Characterization of TRPCs in Neurons. Cells. 2014; 3(2):455-75. PMC: 4092863. DOI: 10.3390/cells3020455. View

15.

Wen H, Ostman J, Bubb K, Panayiotou C, Priestley J, Baker M . 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem. 2012; 287(17):13868-76. PMC: 3340178. DOI: 10.1074/jbc.M111.334896. View

16.

Hofmann T, Obukhov A, Schaefer M, Harteneck C, Gudermann T, Schultz G . Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999; 397(6716):259-63. DOI: 10.1038/16711. View

17.

Liu L, Gu L, Chen M, Zheng Y, Xiong X, Zhu S . Novel Targets for Stroke Therapy: Special Focus on TRPC Channels and TRPC6. Front Aging Neurosci. 2020; 12:70. PMC: 7093711. DOI: 10.3389/fnagi.2020.00070. View

18.

Dietrich A, Gudermann T . TRPC6: physiological function and pathophysiological relevance. Handb Exp Pharmacol. 2014; 222:157-88. DOI: 10.1007/978-3-642-54215-2_7. View

19.

Sabogal-Guaqueta A, Posada-Duque R, Cortes N, Arias-Londono J, Cardona-Gomez G . Changes in the hippocampal and peripheral phospholipid profiles are associated with neurodegeneration hallmarks in a long-term global cerebral ischemia model: Attenuation by Linalool. Neuropharmacology. 2018; 135:555-571. DOI: 10.1016/j.neuropharm.2018.04.015. View

20.

Belayev L, Khoutorova L, Atkins K, Eady T, Hong S, Lu Y . Docosahexaenoic Acid therapy of experimental ischemic stroke. Transl Stroke Res. 2011; 2(1):33-41. PMC: 3037476. DOI: 10.1007/s12975-010-0046-0. View